Levinsson, Anna
de Denus, Simon
Sandoval, Johanna
Lemieux Perreault, Louis-Philippe
Rouleau, Joëlle
Tardif, Jean-Claude
Hussin, Julie
Dubé, Marie-Pierre
Funding for this research was provided by:
Mitacs
Université de Montréal
Molson Foundation
Fondation Institut de Cardiologie de Montréal
Canada Research Chairs
Article History
Received: 7 February 2020
Accepted: 12 January 2022
First Online: 2 February 2022
Competing interests
: M.-P. Dubé has received honoraria from Dalcor and research support (access to samples and data) from AstraZeneca, Pfizer, Servier, Sanofi and GlaxoSmithKline, holds minor equity interest in DalCor, and is an author of a patent on pharmacogenomics-guided CETP inhibition. J.-C.Tardif has received research support from Amarin, AstraZeneca, DalCor, Ionis, Pfizer, RegenexBio, Sanofi and Servier, honoraria from Astra-Zeneca, DalCor, Pfizer, Sanofi and Servier, holds minor equity interest in DalCor, and is an author of a patent on pharmacogenomics-guided CETP inhibition. S. de Denus has received grants from Pfizer, AstraZeneca, Roche Molecular Science and DalCor. All other authors have no competing interests to declare.